Dalbavancin (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Dalbavancin" in English language version.

refsWebsite

Global rank English rank

12nih.gov

4^th place

6doi.org

2^nd place

4web.archive.org

1^st place

4fda.gov

447^th place

338^th place

2europa.eu

68^th place

117^th place

1hres.ca

low place

1canada.ca

1,712^th place

1,063^rd place

1drugs.com

399^th place

333^rd place

1medscape.com

719^th place

636^th place

1reuters.com

49^th place

47^th place

1cdc.gov

218^th place

212^th place

1pharmacist.com

low place

1espacenet.com

800^th place

676^th place

1semanticscholar.org

11^th place

8^th place

1businesswire.com

615^th place

407^th place

1dddmag.com

low place

1dailyfinance.com

low place

9,716^th place

businesswire.com

"Pfizer Will Withdraw Global Marketing Applications for Dalbavancin to Conduct a New Trial" (Press release). Pfizer Inc. 9 September 2008. Archived from the original on 1 August 2019. Retrieved 11 September 2008.

canada.ca

"Drug and medical device highlights 2018: Helping you maintain and improve your health". Health Canada. 14 October 2020. Retrieved 17 April 2024.

cdc.gov

"MRSA | CDC". www.cdc.gov. 5 February 2019.

dailyfinance.com

Durata Therapeutics Announces Phase 3 Clinical Trial Results for Dalbavancin in the Treatment of ABSSSI

dddmag.com

Durata Begins Dalbavancin Study Enrollment. Drug Discovery & Development - 5 October 2011.

doi.org

Micheli G, Chiuchiarelli M, Taccari F, Fantoni M (2023). "The role of long-acting antibiotics in the clinical practice: a narrative review". Infez Med. 31 (4): 449–465. doi:10.53854/liim-3104-4. PMC 10705857. PMID 38075413.
Scheinfeld N (May 2006). "Dalbavancin: a review for dermatologists". Dermatology Online Journal. 12 (4): 6. doi:10.5070/D30WN7D4Q9. PMID 17083861.
Chen AY, Zervos MJ, Vazquez JA (May 2007). "Dalbavancin: a novel antimicrobial". International Journal of Clinical Practice. 61 (5): 853–63. doi:10.1111/j.1742-1241.2007.01318.x. PMC 1890846. PMID 17362476.
Bennett JW, Lewis JS, Ellis MW (February 2008). "Dalbavancin in the treatment of complicated skin and soft-tissue infections: a review". Ther Clin Risk Manag. 4 (1): 31–40. doi:10.2147/tcrm.s46. PMC 2503664. PMID 18728718.
Leuthner KD, Buechler KA, Kogan D, Saguros A, Lee HS (June 2016). "Clinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI)". Therapeutics and Clinical Risk Management. 12: 931–40. doi:10.2147/TCRM.S86330. PMC 4907732. PMID 27354809.
Buckwalter M, Dowell JA (November 2005). "Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide". Journal of Clinical Pharmacology. 45 (11): 1279–87. doi:10.1177/0091270005280378. PMID 16239361. S2CID 42875399.

drugs.com

"Vicuron Pharmaceuticals Submits New Drug Application for Dalbavancin to U.S. Food and Drug Administration". Drugs.com.

espacenet.com

worldwide.espacenet.com

US patent 7119061

europa.eu

ema.europa.eu

"Xydalba EPAR". European Medicines Agency. 17 September 2018. Retrieved 12 February 2022.
European Medicines Agency (EMA) assessment of dalbavancin

fda.gov

"FDA approves Dalvance to treat skin infections". U.S. Food and Drug Administration (FDA). 23 May 2014. Archived from the original on 25 May 2014. Retrieved 12 February 2022.
"FDA Briefing Document: Anti-Infective Drugs Advisory Committee Meeting. NDA 21-883: Dalvance (Dalbavancin) for Injection" (PDF). Food and Drug Administration. Archived from the original (PDF) on 23 June 2017. Retrieved 16 December 2019.

accessdata.fda.gov

"Drug Approval Package: Dalvance (dalbavancin hydrochloride) Lyophilized Powder for Injection NDA #021883". U.S. Food and Drug Administration (FDA). 24 June 2014. Retrieved 21 May 2022.
Summary evaluation

hres.ca

hpr-rps.hres.ca

"Summary Basis of Decision (SBD) for Xydalba". Health Canada. 23 October 2014. Retrieved 29 May 2022.

medscape.com

"Dalbavancin: A Novel Lipoglycopeptide Antibacterial". Medscape.

nih.gov

pubmed.ncbi.nlm.nih.gov

Micheli G, Chiuchiarelli M, Taccari F, Fantoni M (2023). "The role of long-acting antibiotics in the clinical practice: a narrative review". Infez Med. 31 (4): 449–465. doi:10.53854/liim-3104-4. PMC 10705857. PMID 38075413.
Scheinfeld N (May 2006). "Dalbavancin: a review for dermatologists". Dermatology Online Journal. 12 (4): 6. doi:10.5070/D30WN7D4Q9. PMID 17083861.
Chen AY, Zervos MJ, Vazquez JA (May 2007). "Dalbavancin: a novel antimicrobial". International Journal of Clinical Practice. 61 (5): 853–63. doi:10.1111/j.1742-1241.2007.01318.x. PMC 1890846. PMID 17362476.
Das B, Sarkar C, Biswas R, Pandey S (January 2008). "Review: dalbavancin--a novel lipoglycopeptide antimicrobial for gram positive pathogens". Pakistan Journal of Pharmaceutical Sciences. 21 (1): 78–87. PMID 18166524.
Bennett JW, Lewis JS, Ellis MW (February 2008). "Dalbavancin in the treatment of complicated skin and soft-tissue infections: a review". Ther Clin Risk Manag. 4 (1): 31–40. doi:10.2147/tcrm.s46. PMC 2503664. PMID 18728718.
Leuthner KD, Buechler KA, Kogan D, Saguros A, Lee HS (June 2016). "Clinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI)". Therapeutics and Clinical Risk Management. 12: 931–40. doi:10.2147/TCRM.S86330. PMC 4907732. PMID 27354809.
Buckwalter M, Dowell JA (November 2005). "Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide". Journal of Clinical Pharmacology. 45 (11): 1279–87. doi:10.1177/0091270005280378. PMID 16239361. S2CID 42875399.

ncbi.nlm.nih.gov

Micheli G, Chiuchiarelli M, Taccari F, Fantoni M (2023). "The role of long-acting antibiotics in the clinical practice: a narrative review". Infez Med. 31 (4): 449–465. doi:10.53854/liim-3104-4. PMC 10705857. PMID 38075413.
Chen AY, Zervos MJ, Vazquez JA (May 2007). "Dalbavancin: a novel antimicrobial". International Journal of Clinical Practice. 61 (5): 853–63. doi:10.1111/j.1742-1241.2007.01318.x. PMC 1890846. PMID 17362476.
Bennett JW, Lewis JS, Ellis MW (February 2008). "Dalbavancin in the treatment of complicated skin and soft-tissue infections: a review". Ther Clin Risk Manag. 4 (1): 31–40. doi:10.2147/tcrm.s46. PMC 2503664. PMID 18728718.
Leuthner KD, Buechler KA, Kogan D, Saguros A, Lee HS (June 2016). "Clinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI)". Therapeutics and Clinical Risk Management. 12: 931–40. doi:10.2147/TCRM.S86330. PMC 4907732. PMID 27354809.

dailymed.nlm.nih.gov

"Dalvance- dalbavancin injection, powder, for solution". DailyMed. Retrieved 12 February 2022.

pharmacist.com

"Dalbavancin: First I.V. antibiotic for acute bacterial skin infections". Archived from the original on 14 February 2018. Retrieved 3 November 2014.

reuters.com

UPDATE 1-Pfizer says US FDA wants more data on antibiotic. December 2007

semanticscholar.org

api.semanticscholar.org

Buckwalter M, Dowell JA (November 2005). "Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide". Journal of Clinical Pharmacology. 45 (11): 1279–87. doi:10.1177/0091270005280378. PMID 16239361. S2CID 42875399.

web.archive.org

"FDA approves Dalvance to treat skin infections". U.S. Food and Drug Administration (FDA). 23 May 2014. Archived from the original on 25 May 2014. Retrieved 12 February 2022.
"Dalbavancin: First I.V. antibiotic for acute bacterial skin infections". Archived from the original on 14 February 2018. Retrieved 3 November 2014.
"FDA Briefing Document: Anti-Infective Drugs Advisory Committee Meeting. NDA 21-883: Dalvance (Dalbavancin) for Injection" (PDF). Food and Drug Administration. Archived from the original (PDF) on 23 June 2017. Retrieved 16 December 2019.
"Pfizer Will Withdraw Global Marketing Applications for Dalbavancin to Conduct a New Trial" (Press release). Pfizer Inc. 9 September 2008. Archived from the original on 1 August 2019. Retrieved 11 September 2008.